Trending Stock News

$0.24 EPS Expected for iRobot (IRBT); 11 Analysts Bullish Acceleron Pharma Inc. (XLRN)

Among 16 analysts covering Acceleron Pharma (NASDAQ:XLRN), 11 have Buy rating, 1 Sell and 4 Hold. Therefore 69% are positive. Acceleron Pharma had 35 analyst reports since August 13, 2015 according to SRatingsIntel. The rating was reinitiated by Oppenheimer on Monday, February 1 with “Outperform”. On Thursday, September 29 the stock rating was initiated by Citigroup with “Neutral”. The firm has “Buy” rating by Oppenheimer given on Thursday, June 1. The rating was maintained by FBR Capital with “Buy” on Tuesday, June 13. The firm has “Neutral” rating given on Thursday, December 17 by Janney Capital. Barclays Capital maintained Acceleron Pharma Inc. (NASDAQ:XLRN) rating on Monday, June 13. Barclays Capital has “Overweight” rating and $42 target. Credit Suisse maintained the shares of XLRN in report on Tuesday, November 14 with “Outperform” rating. The rating was initiated by Oppenheimer with “Outperform” on Tuesday, December 13. The firm earned “Overweight” rating on Wednesday, April 27 by Barclays Capital. Credit Suisse downgraded Acceleron Pharma Inc. (NASDAQ:XLRN) on Thursday, September 21 to “Hold” rating. See Acceleron Pharma Inc. (NASDAQ:XLRN) latest ratings:

08/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $62.0 Initiate
14/11/2017 Broker: Credit Suisse Rating: Outperform Old Target: $35 New Target: $51 Maintain
02/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $44.0 Maintain
12/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $57 Initiates Coverage On
06/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $40.0 Maintain
21/09/2017 Broker: Credit Suisse Rating: Hold New Target: $35.0 Downgrade
20/09/2017 Broker: Barclays Capital Rating: Overweight Old Target: $42 New Target: $50 Maintain
15/09/2017 Broker: RBC Capital Markets Rating: Sector Perform New Target: $44 Initiates Coverage On
12/09/2017 Broker: UBS Rating: Buy New Target: $50.0 Maintain

Analysts expect iRobot Corporation (NASDAQ:IRBT) to report $0.24 EPS on February, 14.They anticipate $0.25 EPS change or 51.02% from last quarter’s $0.49 EPS. IRBT’s profit would be $6.69 million giving it 64.15 P/E if the $0.24 EPS is correct. After having $0.60 EPS previously, iRobot Corporation’s analysts see -60.00% EPS growth. The stock increased 6.36% or $3.68 during the last trading session, reaching $61.58. About 2.33M shares traded or 98.64% up from the average. iRobot Corporation (NASDAQ:IRBT) has risen 150.93% since February 13, 2017 and is uptrending. It has outperformed by 134.23% the S&P500.

Since September 12, 2017, it had 1 insider purchase, and 12 insider sales for $19.61 million activity. The insider Sherman Matthew L sold $197,868. Shares for $96,134 were sold by Rovaldi Christopher on Tuesday, January 2. Kumar Ravindra had sold 4,300 shares worth $182,363 on Tuesday, January 2. The insider Quisel John D sold $196,423. The insider MCLAUGHLIN KEVIN F sold 16,000 shares worth $614,546. $3.76M worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by George Jean on Friday, December 15. 745,592 shares were bought by CELGENE CORP /DE/, worth $27.59 million on Monday, September 25.

The stock increased 4.46% or $1.75 during the last trading session, reaching $40.98. About 269,615 shares traded. Acceleron Pharma Inc. (NASDAQ:XLRN) has declined 22.43% since February 13, 2017 and is downtrending. It has underperformed by 39.13% the S&P500.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company has market cap of $1.85 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. It currently has negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Investors sentiment increased to 1.81 in Q3 2017. Its up 0.37, from 1.44 in 2017Q2. It increased, as 12 investors sold Acceleron Pharma Inc. shares while 30 reduced holdings. 30 funds opened positions while 46 raised stakes. 37.73 million shares or 12.48% more from 33.54 million shares in 2017Q2 were reported. Omega invested in 50,000 shares. Laurion Cap Mgmt L P has 0.02% invested in Acceleron Pharma Inc. (NASDAQ:XLRN). Moreover, Hudson Bay Capital L P has 0.2% invested in Acceleron Pharma Inc. (NASDAQ:XLRN). Ubs Asset Management Americas Inc owns 325,450 shares for 0.01% of their portfolio. Farallon Mngmt Ltd Company owns 963,000 shares. Meeder Asset invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Fmr Limited Company owns 3.73M shares. Tudor Invest Corporation Et Al accumulated 79,462 shares or 0.08% of the stock. Products Prns Ltd Limited Liability Company holds 0.08% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN) for 64,281 shares. Cubist Systematic Strategies Ltd invested in 0% or 1,506 shares. Loring Wolcott And Coolidge Fiduciary Advisors Llp Ma has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Platinum Investment Management, Australia-based fund reported 58,500 shares. Deerfield Mgmt accumulated 615,000 shares or 1.03% of the stock. Nj State Employees Deferred Compensation Plan stated it has 7,000 shares. Massachusetts-based Westfield Cap Mngmt Co L P has invested 0.44% in Acceleron Pharma Inc. (NASDAQ:XLRN).

Investors sentiment increased to 1.07 in Q3 2017. Its up 0.02, from 1.05 in 2017Q2. It increased, as 34 investors sold iRobot Corporation shares while 67 reduced holdings. 39 funds opened positions while 69 raised stakes. 22.26 million shares or 0.27% less from 22.32 million shares in 2017Q2 were reported. Art Advsrs Ltd Limited Liability Company invested in 0.09% or 23,605 shares. Ameriprise Financial reported 199,328 shares or 0.01% of all its holdings. Manufacturers Life Ins Com The holds 19,974 shares or 0% of its portfolio. Mackenzie owns 65,137 shares or 0.03% of their US portfolio. Advisory Services Ntwk Lc holds 0.03% of its portfolio in iRobot Corporation (NASDAQ:IRBT) for 2,849 shares. Arizona State Retirement System holds 14,367 shares or 0.01% of its portfolio. Barclays Public Limited Company accumulated 34,032 shares. 882 are owned by Pnc Serv Gp. Prudential Fincl owns 52,035 shares. 3.42M are owned by Vanguard Group. State Street stated it has 1.09 million shares or 0.01% of all its holdings. Eqis Capital Management Incorporated reported 15,766 shares. New York State Teachers Retirement holds 0.01% or 45,967 shares. Cubist Systematic Strategies Ltd Liability Company has invested 0.01% in iRobot Corporation (NASDAQ:IRBT). Strs Ohio reported 0% of its portfolio in iRobot Corporation (NASDAQ:IRBT).

Among 13 analysts covering IRobot Corporation (NASDAQ:IRBT), 5 have Buy rating, 0 Sell and 8 Hold. Therefore 38% are positive. IRobot Corporation had 33 analyst reports since September 18, 2015 according to SRatingsIntel. Piper Jaffray maintained iRobot Corporation (NASDAQ:IRBT) on Tuesday, January 2 with “Hold” rating. Piper Jaffray downgraded iRobot Corporation (NASDAQ:IRBT) rating on Monday, January 4. Piper Jaffray has “Neutral” rating and $35 target. Sidoti downgraded the stock to “Hold” rating in Tuesday, January 30 report. The rating was downgraded by Dougherty on Monday, July 3 to “Hold”. The company was initiated on Monday, December 4 by Citigroup. On Wednesday, April 27 the stock rating was maintained by JP Morgan with “Underweight”. The rating was downgraded by on Monday, July 3 to “Neutral”. Dougherty & Company initiated the shares of IRBT in report on Thursday, November 17 with “Buy” rating. The firm earned “Hold” rating on Friday, February 9 by J.P. Morgan. Raymond James downgraded the shares of IRBT in report on Friday, September 18 to “Market Perform” rating.

Since August 29, 2017, it had 0 insider purchases, and 3 selling transactions for $4.38 million activity. The insider Dean Alison sold $3.38 million. $927,100 worth of stock was sold by CHWANG RONALD on Tuesday, August 29. The insider Weinstein Glen Daniel sold $72,800.

Leave a Reply

Your email address will not be published. Required fields are marked *